Efficacy of immunotherapy in obese patients with cancer
Sign Up to like & getrecommendations! Published in 2022 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2022.2061989
Abstract: Abstract Obesity is a condition of excessive fat tissue and high body mass index (BMI ≥30), which is increasing worldwide. Excess body weight is associated with poorer results in cancer treatments; however, recent studies emphasized… read more here.
Keywords: patients cancer; obese patients; immunotherapy obese; efficacy immunotherapy ... See more keywords
Abstract IA-05: Immune health and intratumoral immune heterogeneity: Barriers to the efficacy of immunotherapy in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.panca20-ia-05
Abstract: Pancreatic ductal adenocarcinoma (PDAC) has shown remarkable resistance to immunotherapy including immune checkpoint blockade, vaccines, and other immunomodulatory agents. In cancer, immunosurveillance can be regulated at both the priming and effector phases of an immune… read more here.
Keywords: efficacy immunotherapy; pancreatic cancer; immune health; biology ... See more keywords
Clinical parameters combined with radiomics features to predict the efficacy of immunotherapy for advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e21187
Abstract: e21187 Background: Many tools have been developed to predict the efficacy of immunotherapy, such as LIPI, EPSILoN and mLIPI scores. The aim of this study was to determine the ability of to predict outcomes in… read more here.
Keywords: efficacy immunotherapy; predict efficacy; epsilon; radiomics features ... See more keywords
Identification and Validation of METTL3-Related Molecules for Predicting Prognosis and Efficacy of Immunotherapy in Gastric Cancer Based on m6A Methylome and Transcriptome Sequencing Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.935239
Abstract: Abnormal N6-methyladenosine (m6A) modification levels caused by METTL3 have been identified to be a critical regulator in human cancers, and its roles in the immune microenvironment and the relationship between targeted therapy and immunotherapy sensitivity… read more here.
Keywords: methylation; analysis; gastric cancer; efficacy immunotherapy ... See more keywords